MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

NCT02575339 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Funder Decision

Conditions

Hepatocellular Carcinoma
Liver Cancer
HCC

Interventions

DRUG: MLN0128
DRUG: MLN0128 (RP2D)
DRUG: Sorafenib

Sponsor

Kathy Miller

Collaborators

[object Object]
[object Object]